Ping Chen

US Patent:

6344179, Feb 5, 2002

Filed:

Apr 21, 2000

Appl. No.:

09/553795

Inventors:

Mark M. Goodman - Atlanta GA
Ping Chen - Indianapolis IN

Assignee:

Emory University - Atlanta GA

International Classification:

A61K 5100

US Classification:

424 189, 424 185, 546124, 546132

Abstract:

Provided are compounds of the following formula: wherein R is C2-C6 mono- or multi-unsaturated hydrocarbon having one or more ethylene, acetylene or allene groups, A is 18 or 19, and X is H or halogen. The compounds of the invention bind to dopamine transporter with high affinity and selectivity and are thus useful as diagnostic and therapeutic agents for diseases associated with dopamine transporter dysfunction. The radiolabeled compounds are useful as imaging agents for visualizing the location and density of dopamine transporter by PET imaging.

US Patent:

6399042, Jun 4, 2002

Filed:

Apr 26, 2000

Appl. No.:

09/558916

Inventors:

Mark M. Goodman - Atlanta GA
Ping Chen - Indianapolis IN

Assignee:

Emory University - Atlanta GA

International Classification:

A61K 5100

US Classification:

424 185, 424 189, 546124, 546132

Abstract:

A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes family are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.

US Patent:

20130012493, Jan 10, 2013

Filed:

Mar 22, 2011

Appl. No.:

13/636276

Inventors:

He Zhao - Madison CT, US
Ping Chen - Slingerlands NY, US
Peishan Lin - Schenectady NY, US
Peng Dai - Guilderland NY, US
Jason Louis Davis - Albany NY, US
Duane E. DeMong - Somerset NJ, US
Michael W. Miller - Scotch Plains NJ, US
Xing Dai - Cranford NJ, US
Michael K. Wong - Somerset NJ, US
Brian J. Lavey - New Providence NJ, US
Wensheng Yu - Edison NJ, US
Guowei Zhou - Somerset NJ, US
Andrew W. Stamford - Chatham Township NJ, US
Joseph A. Kozlowski - Princeton NJ, US
William J. Greenlee - Teaneck NJ, US

International Classification:

A61K 31/454
A61P 3/10
C07D 403/12
A61K 31/4178
A61K 31/5386
A61K 31/55
A61K 31/496
C07D 413/14
A61K 31/5377
C07D 498/08
C07D 401/14
C07D 403/14

US Classification:

51421021, 546210, 514322, 548253, 514381, 540603, 51421709, 544370, 51425406, 544139, 5142345, 544105, 5142305

Abstract:

The present invention relates to compounds of the general formula (I): wherein ring A, ring B, G, R, Z, L, and Lare selected independently of each other and are as defined herein, to compositions comprising the compounds, and to methods of using the compounds as glucagon receptor antagonists and for the treatment or prevention of type 2 diabetes and conditions related thereto.

US Patent:

20210363155, Nov 25, 2021

Filed:

May 13, 2021

Appl. No.:

17/320158

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Nicoleta Dobri - New York NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 498/04
C07D 471/04
C07D 487/04
C07D 495/04
A61P 27/02
A61K 31/501
A61K 31/437
A61K 31/4545
A61K 31/5025
A61K 31/506
A61K 31/4375
A61K 31/454
A61K 31/497
C07D 401/06
C07D 405/14
C07D 409/06
C07D 491/052

Abstract:

The present invention provides a compound having the structure:

US Patent:

20210214360, Jul 15, 2021

Filed:

Nov 16, 2020

Appl. No.:

17/099231

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Rando Allikmets - Cornwall on Hudson NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 487/04
C07D 471/04

Abstract:

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt thereof.

US Patent:

20190382409, Dec 19, 2019

Filed:

Jul 24, 2019

Appl. No.:

16/520886

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Rando Allikmets - Cornwall on Hudson NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 487/04
C07D 471/04

Abstract:

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt thereof.

US Patent:

20190031681, Jan 31, 2019

Filed:

Oct 3, 2018

Appl. No.:

16/151019

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Nicoleta Dobri - New York NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 498/04
C07D 471/04
C07D 491/052
C07D 409/06
C07D 405/14
C07D 401/06
C07D 487/04
C07D 495/04

Abstract:

The present invention provide a compound having the structure: (structurally represented) wherein R, R, R, R, and Rare each independently H, halogen, CFor C-Calkyl; Ris H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterocycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

US Patent:

20180237391, Aug 23, 2018

Filed:

Mar 26, 2018

Appl. No.:

15/935918

Inventors:

- New York NY, US
Christopher Cioffi - Albany NY, US
Graham Johnson - Sanbornton NH, US
Nicoleta Dobri - New York NY, US
Emily Freeman - Albany NY, US
Ping Chen - Albany NY, US
Michael Conlon - Albany NY, US
Lei Zhu - Albany NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 209/52
C07D 498/04
C07D 487/04
C07D 471/04
C07D 401/04
C07D 403/06
C07D 403/04
C07D 401/12
C07D 403/12

Abstract:

The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.